San Diego-based Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug sector in February soon after revealing promising details from the mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given to be a weekly injection and in March the compan